252 related articles for article (PubMed ID: 28763307)
1. Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs.
DeAngelo J; Jarrell D; Cosgrove R; Camamo J; Edwards C; Patanwala AE
Am J Ther; 2018; 25(3):e326-e332. PubMed ID: 28763307
[TBL] [Abstract][Full Text] [Related]
2. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
[TBL] [Abstract][Full Text] [Related]
3. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin.
Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA
Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
6. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
[TBL] [Abstract][Full Text] [Related]
7. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.
Holland L; Warkentin TE; Refaai M; Crowther MA; Johnston MA; Sarode R
Transfusion; 2009 Jun; 49(6):1171-7. PubMed ID: 19210325
[TBL] [Abstract][Full Text] [Related]
9. Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study.
Margraf DJ; Seaburg S; Beilman GJ; Wolfson J; Gipson JC; Chapman SA
BMC Emerg Med; 2020 Nov; 20(1):93. PubMed ID: 33243152
[TBL] [Abstract][Full Text] [Related]
10. Emergent reversal of vitamin K antagonists: addressing all the factors.
Martin DT; Barton CA; Dodgion C; Schreiber M
Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
[TBL] [Abstract][Full Text] [Related]
11. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage.
Frontera JA; Gordon E; Zach V; Jovine M; Uchino K; Hussain MS; Aledort L
Neurocrit Care; 2014 Dec; 21(3):397-406. PubMed ID: 24671832
[TBL] [Abstract][Full Text] [Related]
12. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
14. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
[TBL] [Abstract][Full Text] [Related]
15. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate.
Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC
World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122
[TBL] [Abstract][Full Text] [Related]
16. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom.
Guest JF; Watson HG; Limaye S
Clin Ther; 2010 Dec; 32(14):2478-93. PubMed ID: 21353116
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
18. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
[TBL] [Abstract][Full Text] [Related]
19. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
[TBL] [Abstract][Full Text] [Related]
20. Activated Prothrombin Complex Concentrate versus Plasma for Reversal of Warfarin-Associated Hemorrhage.
Rowe AS; Mahbubani PS; Bucklin MH; Clark CT; Hamilton LA
Pharmacotherapy; 2016 Nov; 36(11):1132-1137. PubMed ID: 27726162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
